CLOs on the Move

Organon

www.organon.com

 
At Organon, we envision a better and healthier every day for every woman. The diversity of our business provides a sustainable engine of growth so we can identify and invest in solutions for women. Our mission is to deliver impactful medicines and solutions for a healthier every day. We believe the journey to improve women`s health is critical to achieving a healthier world. We are united in our drive to better support the health of women within our company and around the globe. Together, we work toward our goal of finding solutions for the healthcare issues that matter most to ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $50-100 Million
  • www.organon.com
  • 30 Hudson Street
    Jersey City, NJ USA 07302
  • Phone: 551.430.6000

Executives

Name Title Contact Details
Christian Piccolo
Associate Director, Litigation Profile
Amy Carr
Director, Quality Systems and Compliance Profile
Kirke Weaver
General Counsel and Corporate Secretary Profile
Deborah Telman
General Counsel Profile
Deborah Telman
General Counsel Profile

Similar Companies

Mayfield Brain & Spine

The Mayfield Surgical Innovation Center is a state-of-the-art training facility for spine and cranial surgery technology and minimally invasive procedures.

Savage Laboratories

Savage Laboratories is a Melville, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ripple Therapeutics

The Ripple Therapeutics Epidel® technology is founded on a discovery that drugs can be engineered into controlled release materials without the use of polymers or excipients. The proprietary prodrugs are new chemical entities (NCEs) that have unique properties that allow them to be processed into standalone drug delivery implants (e.g. intravitreal implants, micro/nanoparticles, etc.) or as coatings on medical devices. Ripple Therapeutics implants and coatings are made up entirely from the prodrug without a polymeric carrier to control the implant or drug release properties. The implants and coatings undergo surface erosion to give zero order drug release profiles and are highly engineerable (e.g. different forms, shapes, and sizes) to tailor drug dose and duration for the specific indication of interest. The flexibility in molecular design results in drug doses that are within the therapeutic window, delivering the right amount of drug for the right amount of time. This has the potential to improve patient safety and clinical outcomes.

KeySource

enter your site description here